(Reuters) – AstraZeneca said on Friday its antibody therapy met the main goal of preventing COVID-19 infection in a late-stage study.
The company said the treatment reduced the risk of developing symptomatic COVID-19 by 77%.
(Reporting by Muvija M in Bengaluru; Editing by Sriraj Kalluvila)
